XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare XTL Biopharmaceuticals to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, dividends, institutional ownership and earnings.
Profitability
This table compares XTL Biopharmaceuticals and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XTL Biopharmaceuticals | N/A | N/A | N/A |
| XTL Biopharmaceuticals Competitors | -12,224.09% | -202.33% | -31.23% |
Volatility and Risk
XTL Biopharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals’ peers have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for XTL Biopharmaceuticals and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XTL Biopharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| XTL Biopharmaceuticals Competitors | 9916 | 15312 | 45656 | 1602 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 126.25%. Given XTL Biopharmaceuticals’ peers stronger consensus rating and higher probable upside, analysts plainly believe XTL Biopharmaceuticals has less favorable growth aspects than its peers.
Institutional & Insider Ownership
4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares XTL Biopharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| XTL Biopharmaceuticals | $450,000.00 | -$6.97 million | -2.45 |
| XTL Biopharmaceuticals Competitors | $693.35 million | $8.05 million | -18.80 |
XTL Biopharmaceuticals’ peers have higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
XTL Biopharmaceuticals peers beat XTL Biopharmaceuticals on 7 of the 12 factors compared.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. is an Israeli clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company’s work is centered on treatments intended to regulate abnormal immune-system activity rather than broadly suppressing immune function. XTL’s principal development program has been hCDR1, also known as rigerimod, a synthetic peptide designed to modulate immune responses associated with systemic lupus erythematosus, or lupus. The candidate has been evaluated in clinical development for autoimmune indications, although its regulatory and commercial status may change as the company advances or revises its pipeline.
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
